Eftrenonacog alfa
Alprolix (eftrenonacog alfa) is a fusion protein pharmaceutical. Eftrenonacog alfa was first approved as Alprolix on 2016-05-12. It has been approved in Europe to treat hemophilia b.
| Trade Name | Alprolix |
|---|---|
| Common Name | Eftrenonacog alfa |
| Indication | hemophilia b |
| Drug Class | Fc fusion protein |
